Altimmune Announces CEO Transition as Pemvidutide Approaches Phase 3 Readiness
核心洞察
Altimmune announced that CEO Vipin Garg will step down effective January 1, 2026, with Chairman Jerry Durso assuming the CEO role as the company transitions to late-stage clinical development.
The leadership change coincides with the expected release of 48-week data from the Phase 2b IMPACT trial for pemvidutide before year-end, which will inform Phase 3 trial design.
Pemvidutide, a dual GLP-1 (搜索)/glucagon receptor agonist, has demonstrated meaningful reductions in liver inflammation and fibrosis with significant weight loss in MASH (搜索) patients.
Altimmune announced a strategic CEO succession plan as the late clinical-stage biopharmaceutical company prepares to advance its lead drug candidate pemvidutide into Phase 3 development for metabolic dysfunction-associated steatohepatitis (搜索) (MASH (搜索)). Current CEO Vipin Garg will step down effective January 1, 2026, with Chairman Jerry Durso assuming the dual role of President and CEO.
The leadership transition follows seven years of growth under Garg's direction, during which pemvidutide advanced from a preclinical molecule to a Phase 3-ready program. The company is developing the dual glucagon and GLP-1 (搜索) receptor agonist for MASH (搜索), alcohol use disorder (搜索) (AUD), and alcohol-associated liver disease (搜索) (ALD).
Critical Data Release Expected
The CEO transition is strategically timed with the anticipated release of 48-week data from the Phase 2b IMPACT trial before year-end. These results are viewed as a decisive indicator of pemvidutide's long-term efficacy and safety profile in MASH (搜索) patients. Earlier 24-week data demonstrated promising signals, including meaningful reductions in liver inflammation and fibrosis, along with significant weight loss and impressive tolerability.
"Pemvidutide presents an opportunity to change the standard of care for people with liver disease," said Garg. The drug is a balanced 1:1 dual glucagon and GLP-1 (搜索) receptor agonist that has shown potential to address the competitive MASH (搜索) therapy market.
Regulatory Pathway Forward
Altimmune has scheduled an End-of-Phase 2 meeting with the FDA later this quarter to align on proposed trial design and study endpoints for a Phase 3 MASH (搜索) program. The upcoming 48-week data will include updated non-invasive test (NIT) and weight loss data along with safety and other related metrics, which will inform the regulatory discussions.
New Leadership Profile
Jerry Durso brings over 30 years of life sciences leadership experience, with particular expertise in liver diseases. He most recently served as CEO of Intercept Pharmaceuticals (搜索), where he built a successful rare disease franchise and led the company through its acquisition by Alfasigma. Prior to Intercept, Durso spent over two decades at Sanofi in senior leadership positions, including Chief Commercial Officer roles in the Global Diabetes Division and U.S. Pharmaceuticals business.
"I am very excited to step into the role of CEO as Altimmune embarks on its next phase of growth and prepares to transition to a late-stage clinical company looking toward commercialization," said Durso. "I see significant potential for pemvidutide to bring unique benefits to patients with liver disease."
Financial Foundation
The company maintains a strong financial position with approximately $211 million in liquid assets as of September 2025, providing crucial support for operations through upcoming regulatory and clinical phases. This capital reserve positions Altimmune to advance through Phase 3 development and potential commercialization efforts.
The stock has exhibited considerable volatility, with shares recently testing the upper bounds of their 52-week range following a notable upward trend. Market sentiment currently reflects seven "Buy" ratings from analysts, with expectations hinging on the forthcoming IMPACT trial data.
Garg will serve as an advisor to the company through June 30, 2026, to facilitate a smooth transition during this pivotal period for pemvidutide's development.